Angiogenesis Inhibitor Tested in Mesothelioma Trial

Ariela Katz
Published: Monday, Aug 21, 2017
Nicholas J. Vogelzang, MD
Nicholas J. Vogelzang, MD
Nintedanib, an angiogenesis inhibitor, is being investigated as a first-line treatment for patients with unresectable malignant pleural mesothelioma (MPM). Although it is estimated that malignant mesothelioma represents less than 1% of all cancers, it is a fatal asbestos-associated malignancy1 , and patients with MPM tend to be difficult to treat.

 

Figure. Nintedanib in Malignant Pleural Mesothelioma

Nintedanib in Malignant Pleural Mesothelioma
The FDA has approved nintedanib under the trade name Ofev for the treatment of idiopathic pulmonary fibrosis. As a small-molecule, nintedanib binds competitively to the ATP binding pocket of the VEGF and PDGF receptors, blocking intracellular signaling needed for the proliferation, migration, and transformation of fibroblasts that are essential to the growth of MPM. It also inhibits the Lck, Lyn, and Src nonreceptor tyrosine kinases.3
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x